Our top pick for
Building a portfolio
Genocea Biosciences, Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 72 staff and has a trailing 12-month revenue of around USD$1.4 million.
|52-week range||USD$1.655 - USD$5.75|
|50-day moving average||USD$2.8853|
|200-day moving average||USD$2.5918|
|Wall St. target price||USD$6.68|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.376|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$1.4 million|
|Gross profit TTM||USD$1.4 million|
|Return on assets TTM||-38.87%|
|Return on equity TTM||-256.96%|
|Market capitalisation||USD$144 million|
TTM: trailing 12 months
There are currently 1.7 million Genocea Biosciences shares held short by investors – that's known as Genocea Biosciences's "short interest". This figure is 10.7% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Genocea Biosciences shares can be evaluated.
Genocea Biosciences's "short interest ratio" (SIR) is the quantity of Genocea Biosciences shares currently shorted divided by the average quantity of Genocea Biosciences shares traded daily (recently around 488028.07017544). Genocea Biosciences's SIR currently stands at 3.42. In other words for every 100,000 Genocea Biosciences shares traded daily on the market, roughly 3420 shares are currently held short.
However Genocea Biosciences's short interest can also be evaluated against the total number of Genocea Biosciences shares, or, against the total number of tradable Genocea Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Genocea Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Genocea Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0389% of the tradable shares (for every 100,000 tradable Genocea Biosciences shares, roughly 39 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Genocea Biosciences.
Find out more about how you can short Genocea Biosciences stock.
We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.
Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.
Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $1.655 up to $5.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.6999. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy using neoantigen-targeted peripheral cells for ATLAS identified anti-tumor antigens that are used to manufacture peripheral blood-derived tumor-specific T cell therapy; and GEN-009, a neoantigen vaccine candidate, delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.